BEACON-IPF:bexotegrast 治疗特发性肺纤维化的 2b/3 期研究方案
BEACON-IPF(NCT06097260)是一项随机、双盲、安慰剂对照、剂量探索、无缝衔接的适应性 2b/3 期研究,评估每日一次口服 bexotegrast 治疗特发性肺纤维化 52 周的疗效与安全性。2b 期队列计划纳入 360 例受试者,随机分配至 160 mg、320 mg 或安慰剂组。背景治疗允许使用吡非尼酮或尼达尼布,但限于不超过研究人群的 70%。主要终点是第 52 周绝对用力肺活量相对基线的变化。
要点
- bexotegrast 为每日一次口服的 αvβ6 与 αvβ1 整合素双选择性抑制剂。
- 入组需年龄≥40 岁、IPF 诊断≤7 年、FVCpp≥45%、DLCO(血红蛋白校正)≥30%。
- 背景抗纤维化治疗限用于≤70% 的研究人群,主要终点为 52 周绝对 FVC 变化。
核心结论
- BEACON-IPF 旨在评价 bexotegrast 在 IPF 患者中 52 周的疗效与安全性,主要疗效终点为绝对 FVC 自基线至第 52 周的变化。
研究设计与样本
- 该研究为随机、双盲、安慰剂对照、剂量探索、无缝衔接的适应性 2b/3 期多国多中心试验。
- 2b 期剂量选择队列计划纳入 360 例受试者,按 1:1:1 随机分配至每日一次 bexotegrast 160 mg、320 mg 或安慰剂。
- 2b 期队列完成且选定剂量后,其余 3 期队列继续入组;2b 期接受未选定剂量者可在开放标签研究中接受选定剂量。
- 受试者须为年龄≥40 岁、IPF 诊断≤7 年、FVCpp≥45%、DLCO(血红蛋白校正)≥30% 的成人。
- 背景治疗允许使用吡非尼酮或尼达尼布,但仅限于不超过研究人群的 70%。
主要发现
- 在 2a 期 INTEGRIS-IPF 研究中,bexotegrast 耐受性良好并显示出抗纤维化活性。
- 次要终点包括安全性与耐受性、至疾病进展时间、受试者报告的症状评估以及肺纤维化定量范围。
关键数值与推荐
- 每日一次口服 bexotegrast 160 mg 或 320 mg。
- 随机分组比例为 1:1:1,设安慰剂对照。
- 入组标准包括 FVCpp≥45% 和 DLCO(血红蛋白校正)≥30%。
- 背景治疗用药比例上限为研究人群的 70%。
临床怎么用
- 该研究方案可用于指导特发性肺纤维化患者中 bexotegrast 的剂量选择与疗效评估设计。
- 允许部分患者继续使用吡非尼酮或尼达尼布作为背景治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction Bexotegrast is an oral, once-daily, dual-selective inhibitor of integrins α v β 6 and α v β 1 in development for idiopathic pulmonary fibrosis (IPF). In the phase 2a study INTEGRIS-IPF study (NCT04396756), bexotegrast was well tolerated and showed antifibrotic activity. Methods and analysis BEACON-IPF (NCT06097260) is a randomised, double-blind, placebo-controlled, dose-finding, operationally seamless, adaptive phase 2b/3 study evaluating the efficacy and safety of bexotegrast over 52 weeks in participants with IPF. The phase 2b dose selection cohort will enrol 360 participants randomised 1:1:1 to once-daily bexotegrast 160 mg, 320 mg or placebo. After enrolling the last participant in the phase 2b cohort and while conduct is ongoing, the phase 3 cohort will immediately begin enrolment with a ‘seamless group’ using the same 1:1:1 randomisation. Once the phase 2b cohort has completed and a dose has been selected, the remainder of the phase 3 cohort will be enrolled. Participants in the phase 2b cohort receiving the non-selected dose will be eligible for an open-label study at the selected phase 3 dose. Background therapy with pirfenidone or nintedanib is permitted in ≤70% of the study population. Participants must be adults (≥40 years), have an IPF diagnosis ≤7 years per 2018 international guidelines, per cent predicted forced vital capacity (FVCpp) ≥45% and diffusing capacity for carbon monoxide (haemoglobin adjusted) ≥30%. The primary endpoint is change from baseline in absolute FVC at week 52. Additional endpoints include safety and tolerability, time to disease progression, participant-reported symptom assessments and quantitative lung fibrosis extent. Ethics and dissemination This study was approved by Advarra institutional review board (IRB; OHRP and Food and Drug Administration registration 00000971) and at each participating site by IRBs and local ethics review committees. Participants will provide written informed consent before taking part. Study results will be disseminated in peer-reviewed journals and international conferences targeted to medical, academic and patient communities. Trial registration number NCT06097260 .
引用
- BMJ Open Respiratory Research:Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。